Join the Percutaneous Coronary Intervention group to help and get support from people like you.
Percutaneous Coronary Intervention News
P2Y12 Inhibitor Monotherapy Beneficial for Patients Who Undergo PCI
FRIDAY, June 6, 2025 – For patients who undergo percutaneous coronary intervention (PCI) and discontinue dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy is associated with a lower risk...
FDA Approves Antiplatelet Agent Kengreal (cangrelor) as Adjunct to Percutaneous Coronary Intervention
June 22, 2015 – The U.S. Food and Drug Administration today approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries,...